$2.5 Billion is the total value of DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C)'s 99 reported holdings in Q4 2018. The portfolio turnover from Q3 2018 to Q4 2018 was - .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| ORTX | New | ORCHARD THERAPEUTICS PLCads | $126,211,000 | – | 8,023,600 | +100.0% | 5.05% | – |
| AGN | New | ALLERGAN PLC | $24,059,000 | – | 180,000 | +100.0% | 0.96% | – |
| MOH | New | MOLINA HEALTHCARE INC | $17,639,000 | – | 151,772 | +100.0% | 0.71% | – |
| NTRA | New | NATERA INC | $17,492,000 | – | 1,253,000 | +100.0% | 0.70% | – |
| New | EXACT SCIENCES CORPdbcv 1.000% 1/1 | $16,499,000 | – | 15,000,000 | +100.0% | 0.66% | – | |
| DCPH | New | DECIPHERA PHARMACEUTICALS IN | $12,754,000 | – | 607,633 | +100.0% | 0.51% | – |
| AXGT | New | AXOVANT SCIENCES LTD | $9,960,000 | – | 10,000,000 | +100.0% | 0.40% | – |
| OSMT | New | OSMOTICA PHARMACEUTICALS PLC | $8,821,000 | – | 1,138,256 | +100.0% | 0.35% | – |
| ALLO | New | ALLOGENE THERAPEUTICS INC | $8,801,000 | – | 326,797 | +100.0% | 0.35% | – |
| EXAS | New | EXACT SCIENCES CORP | $8,140,000 | – | 129,000 | +100.0% | 0.33% | – |
| ATNX | New | ATHENEX INC | $7,750,000 | – | 610,700 | +100.0% | 0.31% | – |
| STIM | New | NEURONETICS INC | $3,077,000 | – | 159,000 | +100.0% | 0.12% | – |
| MGTX | New | MEIRAGTX HOLDINGS PLC | $2,256,000 | – | 234,000 | +100.0% | 0.09% | – |
| AXGN | New | AXOGEN INC | $2,138,000 | – | 104,674 | +100.0% | 0.09% | – |
| NEOS | New | NEOS THERAPEUTICS INC | $2,030,000 | – | 1,230,267 | +100.0% | 0.08% | – |
| PTI | New | PROTEOSTASIS THERAPEUTICS IN | $1,358,000 | – | 419,000 | +100.0% | 0.05% | – |
| MNKD | New | MANNKIND CORP | $1,000,000 | – | 943,298 | +100.0% | 0.04% | – |
Other managers
Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2019-02-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| AERIE PHARMACEUTICALS INC | 36 | Q3 2022 | 3.6% |
| CENTENE CORP DEL | 30 | Q3 2023 | 3.0% |
| BIOCRYST PHARMACEUTICALS INC | 29 | Q3 2023 | 2.2% |
| MOLINA HEALTHCARE INC | 26 | Q3 2022 | 1.7% |
| EHEALTH INC | 25 | Q3 2020 | 2.0% |
| INTERCEPT PHARMACEUTICALS IN | 24 | Q1 2023 | 2.2% |
| MYLAN NV | 23 | Q3 2020 | 6.2% |
| PORTOLA PHARMACEUTICALS INC | 23 | Q1 2019 | 6.0% |
| BROOKDALE SR LIVING INC | 23 | Q3 2023 | 2.2% |
| ALIMERA SCIENCES INC | 23 | Q3 2019 | 0.8% |
View DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C)'s complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| DA32 Life Science Tech Acquisition Corp. | August 01, 2023 | 5,145,000 | 91.1% |
| CareMax, Inc. | March 13, 2023 | 18,691,423 | 16.4% |
| CareMax, Inc. | June 02, 2022 | 18,691,423 | 20.7% |
View DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C)'s complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 4 | 2024-06-14 |
| 4 | 2024-06-03 |
| 13F-HR | 2024-05-15 |
| 3 | 2024-03-19 |
| 4 | 2024-03-19 |
| 4 | 2024-03-12 |
| 3 | 2024-03-08 |
| 4 | 2024-02-16 |
| 13F-HR | 2024-02-14 |
| 4 | 2024-02-08 |
View DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C)'s complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.